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Abstract: A novel approach was developed for the coencapsulation of an anti-HIV drug (teno-
fovir) and a latency-breaking agent (vorinostat), using magnetically guided layer-by-layer (LbL) 
assembled nanocarriers for the treatment of neuroAIDS. Ultrasmall iron oxide (Fe
3
O
4
) nanopar-
ticles (10±3 nm) were synthesized and characterized. The LbL technique was used to achieve a 
sustained release profile, and application of 2 bilayers ([tenofovir+dextran sulphate]
2
+vorinostat)
to magnetic nanoparticles resulted in a 2.8 times increase in drug (tenofovir) loading and also 
resulted in an increase in the drug release period by 30-fold, with 100% drug release in sustained 
manner over a period of 5 days with the simultaneous stimulation of latent HIV expression. 
Nanoformulation showed a good blood–brain barrier transmigration ability (37.95%±1.5%) 
with good in vitro antiviral efficacy (~33% reduction of p24 level) over a period of 5 days 
after HIV infection in primary human astrocytes, with good cell viability (.90%). Hence, LbL 
arrangements of drugs on magnetic nanoparticles provides sustained release and, therefore, may 
improve the patient’s adherence to therapy and lead to better compliance.
Keywords: layer-by-layer, magnetic nanocarriers, blood–brain barriers, neuroAIDS, sustained 
release, anti-HIV drug, latency
Introduction
Ever since the introduction of combination antiretroviral therapy (ART), HIV-infection-
related morbidity and mortality have dramatically decreased. However, none of the 
currently available antiretroviral agents provides a cure. HIV infection has now become 
a chronic disease requiring a lifelong commitment to daily oral treatment.1 Highly 
active ART (HAART) comprises complex regimens that require strict adherence to 
complicated treatment schedules, and the quality of treatment depends on the patient’s 
adherence to the recommended regimens. Antiretroviral adherence is the second 
strongest predictor of progression to AIDS and death, after CD4 count.2,3 Incomplete 
adherence to ART, however, is common in all groups of treated individuals. The aver-
age rate of adherence to ART is approximately 70%, despite the fact that long-term 
viral suppression requires near-perfect adherence.4,5 Most antiretroviral drugs have 
a short half-life and, in turn, need be in circulation constantly to control the virus 
replication. It is believed that missing a medication dose even once can provide an 
opportunity for viruses to replicate such that a medication-resistant HIV strain may 
develop. Patient nonadherence can be a pervasive threat to health and well-being and 
can carry an appreciable economic burden. Despite all the best intentions and efforts 
on the part of health care professionals, a patient’s noncompliance in the case of HIV 
therapy (HAART) is very high.4 As per clinical trial data on HIV drugs, results show 
that missed doses of antiretroviral agents were most likely to occur because of forget-
ting (43%), sleeping through a dose (36%), being away from home (32%), changing 
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one’s routine (27%), being too busy to take the dose (22%), 
feeling sick (11%), and experiencing depression (9%).5,6 
These shortfalls of nonadherence have serious and detri-
mental effects from the perspective of disease management 
and treatment.7 Although no single intervention strategy can 
improve the adherence of all patients in HIV, and attempts 
to improve patient adherence depend on a set of key factors, 
reduction of dosing frequency can lead to efficient patient 
compliance.
HAART only helps in suppressing HIV replication, but 
it does not clear virus from infected individuals. Various 
reservoirs of replication-competent HIV have been identi-
fied that may contribute to this persistence. Several attempts 
have been made to clear the latent HIV reservoir, but these 
attempts have not been successful in eliminating all latently 
infected cells or in preventing virus rebound on cessation 
of therapy.8 In addition, efforts should be made to target 
hidden latent virus in the body’s sanctuaries, such as the 
brain, which serves as one of the sources of virus production 
to the periphery. Vorinostat, a histone deacetylase inhibi-
tor, has shown great promise to break latency in CD4+ T 
cells, and recent studies also have shown that other agents 
(tumor necrosis factor, interleukin 1β, and bryostatin) are 
being used as HIV-reactivating agents to break latency; nev-
ertheless, the effect of vorinostat on the neuronal reservoir 
has not yet been established.9,10 Scientists are exploring a 
variety of strategies in the hope of either completely eradi-
cating HIV from the body (a sterilizing cure) or reducing 
it to such a low level that the immune system can maintain 
control without antiretroviral drugs (a functional cure). 
Among these strategies are agents that flush HIV out of 
latent reservoirs, drugs that keep hidden virus permanently 
inactive, and immune-strengthening therapies that protect 
cells from infection. The general scientific consensus is 
that a cure will likely require a combination approach. 
In spite of significant advances in HAART, the elimina-
tion of HIV-1 reservoirs from the central nervous system 
remains a formidable task.11–13 This is mainly attributed to 
the inability of ART to penetrate the blood–brain barrier 
(BBB) and deprived the brain from the drug effects.10,14–16 
Long-acting formulations of therapeutic agents have been 
used to improve adherence and prevent issues such as 
missing doses or treatment fatigue to prescribed medica-
tion in a number of different fields such as contraception, 
male hypogonadism, and schizophrenia, with demonstrable 
success.17 Therefore, as suggested earlier, the sustained 
release formulation of latency-breaking agents, together 
with antiretroviral drugs, could serve a multifunctional 
purpose and help eradicate HIV. Where sustained drug 
release may cause reduced adherence, a combination of 
latency-breaking and anti-HIV agents could eradicate a viral 
reservoir. The practice of nanotechnology in nanomedicine 
has shown exciting prospects for the development of a novel 
drug delivery system to achieve the desired therapeutic lev-
els of anti-HIV drugs and HIV-reactivating agents across the 
BBB.18–21 In a nutshell, we need to deliver the drugs across 
the brain, activate the latent HIV, and subsequently release 
HIV drugs from the carrier at a constant rate for a longer 
period to increase therapeutic adherence and eradicate the 
activated HIV reservoir without hampering the integrity of 
the BBB. Considering these scenarios, we have developed 
a novel, nanoengineered layer-by-layer (LbL) assembly of 
an anti-HIV drug (tenofovir) and a latency-breaking agent 
(vorinostat) on ultrasmall magnetic nanoparticles (MNPs) to 
achieve the sustained release of the drug for 5–7 days. The 
movement of MNPs can be “remote controlled” for its effec-
tive penetration across the BBB by applying an external 
magnetic force, as shown in the schematic in Figure 1.
Complementarily, LbL arrangements of drugs on MNPs 
will provide sustained release, therefore improving bio-
availability and the patient’s adherence to medication. The 
formulation assembly and underlying drug release mecha-
nism from nanoengineered assembled MNP is represented 
in Figure 2.
Our current work is a proof-of-concept study demonstrat-
ing that an HIV latency-breaking agent (vorinostat) can be 
packaged into nanoparticles in conjunction with an antiretro-
viral drug (tenofovir). We have designed a formulation that 
uses nanotechnology to simultaneously reactivate and kill 
HIV in a sustained manner for 5 days across the BBB, which 
will be beneficial for the treatment of neuroAIDS. Therefore, 
our work provides a platform for more effective HIV therapy 
and possible future eradication of the virus.
Materials and methods
synthesis of ultrasmall MNPs
The ultrasmall Fe
3
O
4
 MNPs were synthesized according 
to the coprecipitation method proposed by Sun et al22 with 
minor modifications. All glassware was cleaned overnight 
by aqua regia before being used for the reactions. Briefly, a 
solution of 3 mL FeCl
3
 (0.487 g dissolved in 2 mol/L HCl) 
and 10.33 mL H
2
O was stir-mixed with 2 mL Na
2
SO
3
 (0.126 g 
in 2 mL of water) drop by drop over the course of a minute. 
On the change in color from yellow to red-light yellow, 
this solution was mixed into 80 mL NH
3
+H
2
O (0.85 mol/L) 
under vigorous stirring. A black precipitant quickly formed, 
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1st tenofovir layer
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Figure 1 Nanoformulation delivery across the blood–brain barrier (BBB).
Notes: Proposed schematic of magnetic nanoparticle-based antiretroviral drug delivery across the BBB under the influence of an external noninvasive magnetic force.
which was allowed to crystallize further, for approximately 
30 minutes, under continuous stirring. The suspension was 
washed, and formation of stable MNPs was achieved by 
adjusting the pH from 3.0 to 7.5 and the temperature from 
90°C for first 5 minutes to 100°C for about 1 hour. A change 
in color from black to reddish-brown suggests the formation 
of compact MNPs, which are washed with water at least three 
times by the decantation method.
characterization of MNPs and drug 
efficiency: X-ray diffraction and 
transmission electron microscopy analysis
Structural conformation of MNPs was determined by 
Shimadzu XRD-7000 diffractometer (Shimazdu, Tokyo, 
Japan). Transmission electron microscopy of MNPs was 
performed with the Phillips CM-200 200 kV transmission 
electron microscope operated at 80 kV. In brief, one drop 
of MNPs was spread on carbon support film on 400 mesh 
Cu grids (type B; Ted Pella, Inc., Redding, CA, USA). For 
better contrast during transmission electron microscopy 
imaging, samples on the grid were negatively stained 
with phosphotungstic acid (2.0% w/v; pH 6.4) and dried 
at room temperature. The size distribution and surface 
charge measurement of MNPs were carried out at 25°C in 
dynamic laser scattering (Zetasizer NanoZS, Malvern). The 
measurement of super paramagnetism was carried out by 
a classical vibrating sample magnetometer (Model 4 HF 
VSM, ADE, Lowell, MA, USA). The magnetic hysteresis 
loops of the Fe
3
O
4
 particles were measured between +1,200 
and −1,200 Oersted at room temperature.
Time kinetics and drug-binding isotherm 
on MNPs
For determining the time kinetics of direct binding of tenofo-
vir on MNPs, 1 mg/mL tenofovir solution to 1 mg MNPs was 
incubated in PBS buffer (pH 7.4) for 0.5, 1, 1.5, and 2 hours 
at room temperature. The amount of bound drug or percent-
age binding to the MNPs was determined by estimating the 
concentration of tenofovir in unbound fraction (supernatant) 
of the mixture by the spectrophotometric method at an 
ultraviolet absorbance of 260 nm. In addition, the effect of 
different drug concentrations (1–4 mg/mL) with respect to 
drug binding was calculated. For vorinostat, time kinetics 
and percentage drug binding were calculated as described 
earlier, and calculated using ultraviolet spectrophotometry 
at of 240 nm.
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Figure 2 Formulation assembly and drug release mechanism.
Notes: (A) schematic representation of formulation design. (B) Simplified illustration of the drug release mechanism from magnetic layer-by-layer assembled nanocarriers. 
(i) Diffusion-based drug release through pores. (ii) Drug release via surface hydrolysis of polymer chains of polyelectrolyte assembly.
lbl coatings on nanocarriers
A nanoengineered LbL self-assembly technique was used 
for nanoparticle coatings, as described by Decher.23 The 
polyelectrolyte pairs used for this experiment were dextran 
sulphate (polyanion: 2 mg/mL in 0.15 M NaCl; molecular 
weight, 500,000) and tenofovir (polycation: 1 mg/mL in PBS; 
molecular weight, 287.213 g/mol). In brief, a solution of 
2 mg/mL concentration of dextran sulphate sodium (DS) was 
prepared with 0.15 M NaCL, with pH adjusted to 7.4. For the coat-
ing, 100 µL DS was added to 1 mg drug-loaded MNPs and kept 
at room temperature for 20 minutes with intermittent shaking. 
The nanoparticles were then centrifuged at 2,500 rpm 
for 3 minutes to separate them from the unreacted DS solution 
and were washed with Milli-Q water. Later, 100 µL (1 mg/mL) 
positively charged drug (ie, tenofovir) was added for second-
layer deposition to nanocarriers and held for 20 minutes 
of intermittent shaking. Finally, coated nanocarriers were 
washed twice with distilled water, using centrifugation. 
A similar process can be repeated two times to have 2 bilayer 
coatings on MNPs, and the surface charge of the MNPs was 
measured, using the zeta potential analyzer, after rinsing 
and before the addition of each layer. Finally, a vorinostat 
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(concentration, 0.05 mg/mL) layer was deposited to a bilayer 
(tenofovir+DS)
2
 system. The final assembled nanoformula-
tion was washed with distilled water, using centrifugation, 
and used for release studies.
In vitro drug release pharmacokinetic 
study
In vitro drug release studies were performed on uncoated 
MNPs and polyelectrolyte-coated assembled nanoformula-
tion. Drug-loaded uncoated and coated MNP formulations 
were transferred to an Eppendorf tube containing 150 µL 
0.01 M PBS buffer (pH 7.4). The samples were incubated 
at 37°C in an incubator, and at preset interval times (every 
15 minutes), the release medium was collected and replaced 
with fresh buffer solution to maintain the sink condition. 
The cumulative percentage drug release data were obtained 
using amount of drug release from the total drug content and 
was determined spectrophotometrically at a λ
max
 of 260 and 
240 nm for tenofovir and vorinostat, respectively. Statistical 
analysis of the data was performed using analysis of variance 
(single factor). Difference was considered significant when 
P,0.05.
Intracellular uptake analysis
Primary human astrocytes (HAs) were seeded on cover 
slips in six-well plates with a concentration of 1×106 cells. 
After 24 hours, cells were treated with an equal quantity of 
nanoformulation in the presence and/or absence of external 
magnetic forces for 6 hours. Cells were rinsed three times 
with PBS and fixed with 4% paraformaldehyde in PBS for 
30 minutes at room temperature. Cover slips were mounted 
on the slides with Prolong®Gold antifade reagent (Invitro-
gen, USA), and fluorescent intensity was detected using 
a TCS SP2 Confocal Laser Scanning Microscope (Leica 
Microsystems, Wetzlar, Germany).24 Confocal images were 
obtained at 488 nm with an argon-ion laser with objective 
lens at 20× with electronic zoom settings. To quantify the 
cellular uptake of nanoparticle levels, flow cytometry was 
used.25 HAs were treated with different concentrations of 
fluorescein isothiocyanate (FITC)-tagged nanoformulation 
(50, 100, and 200 µg/mL). The cells were then harvested at 
24 hours after treatment and were counted; equal amounts of 
cells (1×106) were aliquoted in 12×75 mm polystyrene falcon 
tubes (catalog 352058; BD Biosciences, San Jose, CA, USA) 
and fixed with Cytofix solution (BD Bioscience). Cells were 
acquired on an Accuri C6 flow cytometer (BD Accuri, Ann 
Arbor, MI, USA) and analyzed with FlowJo software (Tree 
Star, Inc., Ashland, OR, USA). A total of 10,000 events were 
collected for each sample. Cells were gated on the basis of 
cells with and without nanoformulation controls. Cells posi-
tive for nanoformulation are shown in Figure 8 as colored 
histograms with shifted mean fluorescence intensity (MFI) 
compared with controls.
In vitro BBB preparation and 
transmigration assay
Primary human brain microvascular endothelial cells and 
HA cells were cultivated as per the provider’s recommen-
dations (ScienCell Research Laboratories, CA, USA). The 
BBB model was established as described by Persidsky et 
al.26 In brief, the in vitro BBB model was developed in a 
bicompartmental transwell culture plate (product 3415; 
Corning Life Sciences, Mexico). The upper chamber of 
this plate is separated from the lower one by a 10 µm thick 
polycarbonate membrane possessing 3.0 µm pores. In a 
sterile 24-well cell culture plate with a pore density of 2×106 
pores/cm2 and a cell growth area of 0.33 cm2, 2×105 human 
brain microvascular endothelial cells and HAs were grown 
to confluence on the upper chamber and underside of the 
lower chamber, respectively. To access the effect of MNP 
nanoformulation on the integrity of the in vitro BBB model, 
after transmigration assay, paracellular transport of FITC-
dextran was measured.15 Briefly, 100 mg/mL FITC-dextran 
(Sigma-Aldrich, St Louis, MO, USA) was added to the upper 
chamber of the inserts and further incubated for 6 hours. Sam-
ples were collected from the bottom chamber after 6 hours, 
and relative fluorescence was measured at excitation wave-
length 485 nm and emission wavelength 520 nm, using a 
Synergy HT multimode microplate reader (BioTek Instru-
ments, Inc., Winooski, VT, USA) multimode microplate 
reader instrument. FITC-dextran transport was expressed as 
percentage FITC-dextran transported across the BBB into 
the lower compartment compared with negative control. 
Intactness of in vitro BBB was determined by measuring the 
transendothelial electrical resistance (TEER), using Millicell 
ERS microelectrodes (Millipore). Transmigration study of 
drug-loaded MNP was conducted on the fifth or sixth day 
of the BBB culture, when ideal integrity of this membrane 
was achieved, as established by TEER measurement. MNP 
formulation was added to the apical chamber and incubated at 
37°C in the presence or absence of a magnetic force of 0.08 T 
placed externally, below the transwell basolateral chamber. 
MNP nanoformulation was collected from lower chambers 
at 6 hours, and percentage transmigration was analyzed at 
different points, using an ammonium thiocyanate-based 
photometric assay.18
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cytotoxicity assay
Cytotoxicity was assessed by MTT cell viability assay, using 
a CellTiter 96®Aqueous one-solution cell proliferation assay 
kit (catalog G3580; Promega, USA).19 HAs were seeded in 
96-well tissue plates at a density of 5×103 cells per well. After 
24 hours of incubation at 37°C, culture medium was replaced 
with 100 µL fresh media containing different concentra-
tions of Fe
3
O
4
 (50–250 µg/mL). Twenty microliters MTT 
solution (5 mg/mL in PBS) were added into each well after 
24 hours posttreatment and incubated at 37°C for 2 hours. 
Finally, 100 µL stop solution (20% sodium dodecyl sulfate 
in 50% dimethyl formamide) was added into each well, and 
absorbance was recorded at 550 nm by a microplate reader 
(Synergy HT; BioTek Instruments, Inc.).
activation of latent hIV, using vorinostat 
and in vitro antiviral efficacy of the 
nanoformulation
To confirm the activation of latent cells and check the anti-
viral efficacy of the drug after the magnetic-triggered release 
process, we conducted a p24 antigen estimation. The cells 
were activated by treating them with polybrene (10 µg/mL) 
for 6 hours before the infection. HAs (10×106 cells) were 
infected with HIV-1Ba-L (catalog #510; National Institutes 
of Health AIDS Research and Reference Reagent Program) 
overnight, as described by Atluri et al,24 washed with PBS and 
returned to culture with and without standard drug solution 
(tenofovir and vorinostat) or drug-loaded nanoformula-
tion at equimolar concentrations. The culture supernatants 
were quantitated for p24 antigen, using an enzyme-linked 
immunosorbent assay kit (ZeptoMetrix, NY, USA) on the 
third, fifth, and seventh days postinfection, expressed as 
picograms per milliliter.
statistical analysis
Experiments were performed at least three times in dupli-
cate, unless otherwise indicated in the figure legends. The 
values obtained were averaged, and data are represented as 
the mean ± standard error. All the data were analyzed using 
GraphPad Prism software. Comparisons between groups 
were performed using one-way analysis of variance. Differ-
ences were considered significant at P#0.05.
Results
Formulation characterization and drug-
release kinetics
Ultrasmall magnetite nanoparticles were prepared and char-
acterized for size, shape, crystallinity, and drug loading. 
Transmission electron microscopy shows that nanoparticles 
were in the range of 10±3 nm, as shown in Figure 3A, with 
excellent dispersion properties (polydispersion index .0.81) 
in aqueous medium. In addition, the effect of drug loading 
and LbL deposition on MNP with respect to its hydrodynamic 
diameter also was determined (data shown in Figure S1). 
Magnetic hysteresis loops for MNP displayed strong magnetic 
behavior (exhibited by a superparamagnetic property with no 
coercivity and remanence), when measured between +1,200 
and −1,200 Oersted at room temperature (as shown in 
Figure 3B). The crystal structure of synthesized magnetite 
particles was confirmed by X-ray diffraction spectroscopic 
measurement (Figure 3C). The X-ray spectrum consists of 
magnetite-specific peaks that correspond to 220, 311, 400, 
511, and 440 planes. The encapsulation efficiency of teno-
fovir-loaded (35%±8%) and vorinostat-loaded (25%±8%) 
uncoated MNPs were calculated.
LbL assembly deposition was confirmed using zeta poten-
tial analysis; results show that the zeta-potential value for 
uncoated MNPs coated with tenofovir was +8.62±1 mV, which 
reversed on adsorption of drug DS coating to −29.3±3 mV and 
kept on reversing on subsequent layer deposition, as shown 
in Figure 3D, thus confirming that layer deposition is taking 
place, as desired and predicted. Results showed (Figure 3E) 
that application of 1 layer of DS leads to 1.9 times 
(32–62.5 µg/mg MNPs) higher drug encapsulation and, in 
the case of 2 bilayers (2BL), loading increases to 2.8 times 
(32–90.7 µg). The pharmacokinetic release studies show 
that uncoated MNPs release 100% drug in 4 and 7 hours, 
respectively, for tenofovir and vorinostat. The application 
of LbL assembly (1 layer and 2BL) increases the tenofovir 
release duration from 48 to 120 hours, as shown in Figure 4 
(inset shows the initial 4 hour burst release data for all type 
nanoformulations). To confirm the structural and functional 
integrity of the drug after the release process, mass spec-
trometry analysis (details given in Figure S2) of the drug 
(tenofovir) was performed before (standard drug) and after 
the release (results shown in Figure S3).
In vitro BBB characterization and 
formulation transmigration assay
The BBB transmigrability of the plain MNPs and MNPs-2BL 
drug-loaded nanoformulation was evaluated using an in vitro 
human BBB model. The intactness of grown BBB was deter-
mined by TEER values. After the TEER determination, MNP 
nanocarriers were subjected to different wells, either in the 
presence or the absence of external magnetic force. As shown 
in Table 1, initial TEER values of all treatment groups were 
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Abbreviation: MNP, magnetic nanoparticle.
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similar to standard 200±5 ohms/cm2. A schematic of proposed 
mechanisms of transmigration across BBB has been depicted 
in Figure 1. As expected, there was no difference found in the 
formulations value (results shown in Table 1) when compared 
with uncoated and unloaded MNP carriers.
Formulation ability with respect to BBB transmigration 
was verified by measuring the iron concentration after applica-
tion of the external magnetic field. As evident from Figure 5A, 
40%±3% of plain MNP versus 31.8%±3.5% of final nanofor-
mulation ([MNP+tenofovir]
2
+vorinostat) crosses the BBB in 
the presence of 0.8 T magnetic fields in 6 hours.
Without application of external magnetic force, only 
2%±1.5% of the formulations were able to cross the BBB 
in 6 hours (result not shown). Furthermore, the integrity of 
BBB was evaluated using paracellular transport of FITC-
dextran, as described earlier,27 where the FITC molecule 
was used as a detection moiety to confirm the membrane 
intactness. Figure 5B shows that only 7–8%±2% of the 
FITC molecule was detected in the transmigration (apical to 
basolateral chamber) in the entire nanoformulation treatment 
sample compared with ~100% in the case of negative control 
(without any BBB cells), thus showing that transmigration 
of MNP nanoformulation under external magnetic field does 
not affect the BBB integrity
In vitro cytotoxicity and cellular 
uptake studies
To evaluate the cytotoxicity of nanoformulation, we per-
formed the MTT cytotoxicity assay on HAs. Results show 
(Figure 6) that treatments with different concentrations 
(50–200 µg/mL) of nanoengineered MNP nanoformula-
tion do not show any cytotoxicity, and the percentage of 
viable cells was similar to untreated control, suggesting 
that doses of nanoformulation are nontoxic and have no 
significant safety concerns. Experiments were also con-
ducted in neuronal cells and peripheral cells, and there were 
no cytotoxic effects observed (data shown in Figure S4 for 
neuronal cells).
In addition, the qualitative and quantitative analysis of 
formulation, in terms of cellular uptake, was performed 
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Figure 5 In vitro blood brain barrier model characterization.
Notes: (A) Magnetic nanoparticle (MNP) nanoformulation transmigration across an in vitro blood–brain barrier model. Magnetic nanoformulation was added in the upper 
chamber of the blood–brain barrier model with a magnet placed underneath for the duration of experiment. at 6 hours after plating, migrated plain MNPs and nanoformulations 
were calculated for iron content in the lower chamber. results are expressed as mean ± standard error of three independent experiments. Statistical significance was 
determined using unpaired student’s t-test. (B) Effect of nanoformulation on fluorescein isothiocyanate-dextran transport in the blood–brain barrier model. Fluorescein 
isothiocyanate-dextran transport was measured in blood–brain barrier model after 6 hours of magnetic treatment. FITc-dextran was added on the upper chamber of the 
insert. After 6 hours of incubation, relative fluorescence units from the basal chambers of the inserts were measured. Results were expressed as percentage fluorescein 
isothiocyanate-dextran transport with respect to the untreated control cultures (negative control = no cell and positive control = with cells) and represented as mean ± 
standard error of independent experiments. Ns indicates when P-value was found to be more than 0.05, then the result would be considered statistically not significant.
Abbreviation: FITC, fluorescein isothiocyanate.
Table 1 Transendothelial electrical resistance values of the in vitro blood–brain barrier model before and after treatment of nanocarriers 
(coated and uncoated) in the presence and absence of external magnetic force
Transendothelial electrical  
resistance values, ohms/cm2
Untreated well  
(control)
Plain magnetic  
nanoparticles
Drug-loaded magnetic  
nanoparticles
Two bilayer coated 
magnetic nanoformulation
Before treatment 198.2±7.9 201.2±6.5 197.2±5.9 194.3±5.6
after magnetic treatment 192.6±5.8 198.4±7.5 190.2±6.2 196.2±4.3
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using the same concentrations (50–200 µg/mL). Confocal 
microscopy was used to visualize the MNP nanoformula-
tion particle uptake at different points (range, 6–24 hours). 
Figure 7 represents the cellular uptake of formulation in HAs 
after 6 hours of nanoformulation treatment at 100 µg/mL 
concentration.
For quantitative analysis, a flow cytometer was used. 
Our results show a concentration-dependent increase in the 
 percentage of cells positive for FITC-tagged nanoformula-
tion: As the concentration increased from 50 to 200 µg/mL, 
there was 1.25-fold (ie, 35.7% to 44%) increase in the per-
centage of cells positive for FITC-tagged nanoformulation, as 
shown in Figure 8 after 24 hours of treatment. Furthermore, 
when we analyzed the MFI, as shown in the legend, there 
was a significant concentration-dependent increase in MFI; 
for instance, a MFI of 59,395 was observed for 50 µg/mL 
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Figure 6 cell viability of human astrocytes with magnetic nanoparticle nanoformulation.
Notes: results show the percentage of cells viable after treatment with different concentrations of nanoformulation (50–200 µg/ml) for 24 hours.
DAPIBF image
NP Composite
Figure 7 Cell uptake of fluorescein isothiocyanate-tagged magnetic nanoparticle nanoformulation (concentration, 100 µg/ml) in primary human astrocyte after 6 hours 
of treatment.
Notes: Composite image shows green (drug-loaded 2-layer formulation) and blue (cell nuclei) fluorescence inside the cells, and thus confirms the cellular uptake of the 
nanoformulation. Images were taken at 10× magnification (inset image magnifications, 20×), using fluorescence microscopy (Leica, Wetzlar, Germany).
Abbreviations: BF, bright field image; DAPI, 4′,6-diamidino-2-phenylindole, dihydrochloride; NP, nanoparticle.
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Figure 8 Quantitative analysis of fluorescein isothiocyanate-tagged magnetic nanoparticle nanoformulation after 24 hours of treatment in primary human astrocytes by flow 
cytometry.
Notes: Data suggest that an increase in concentration from 50 to 200 µg/mL leads to an increase in the percentage of cells positive for fluorescein isothiocyanate-
tagged nanoformulation, as well as an increase in mean fluorescence intensity. Ten thousand events were collected for each sample. Cells were gated on the basis of cells 
without nanoformulation (brown line histogram) and nanoformulation alone (blue dotted-line histogram) controls. cells positive for nanoformulation are shown as colored 
histograms with shifted mean fluorescence intensity compared with controls. Colored histograms on (A–C) represent cells treated with 50 (blue), 100 (red), and 200 (green) 
µg/mL fluorescein isothiocyanate-tagged nanoformulation, which shows a 35.7%, 40%, and 44% increase in cells positive for nanoformulation and 59,395, 77,380, and 139,109 
mean fluorescence intensity, respectively. Histograms on (D) show an overlay of all three concentrations (50, 100, 200 µg/ml).
Abbreviations: FL, fluorescence; MNP, magnetic nanoparticle.
concentration, which increased to 139,109 (ie, 2.3-fold) 
when concentration was increased to 200 µg/mL. Overall, 
it is relevant to point out that the increase in MFI correlated 
with an increase in the percentage of cells positive for 
FITC-tagged nanoformulation, and that both increases were 
concentration-dependent.
latency-breaking and in vitro antiviral 
efficacy of the nanoformulation
Latency-breaking and antiviral efficacy of the nanoformula-
tion was determined via quantification of p24 antigen in the 
HA infection model.19 Our group reports for the first time 
that vorinostat significantly activates latent HIV infection 
in the neuronal cells.28 Different concentrations (0.5–5 µM) 
of vorinostat (solution phase) were tested for the latency-
breaking ability; the results showed that a 1 µM concentration 
yields a significant difference in p24 value (data shown in 
Figure S5) and was used for the final formulation development. 
To confirm the efficacy of the nanoformulation after the 
magnetic-triggered release process after 24 hours, we con-
ducted a p24 viral replication assay, the results of which 
showed (Figure 9) that standard tenofovir (1 mg/mL solu-
tion), and MNPs-2BL nanoformulation showed equal p24 
inhibition efficacy after the third day postinfection, thus 
suggesting that the integrity and efficacy of the drug are not 
lost after external magnetic application.
The results show a good latency-breaking ability for 
vorinostat-loaded MNPs (20.5% increase) when compared 
for p24 levels, with respect to positive control (HIV-infected 
HA cells), as shown in Figure 10 on day 1 of nanoformula-
tion treatment. The sustained-release ability of the finally 
assembled nanoformulation ([MNP+tenofovir]
2
+vorinostat) 
was also evaluated over a treatment period of 5 days in the 
HA model.
Our results showed that there was a significant suppres-
sion of viral load (~33%; 390–260 pg/mL) reduction of p24 
level found after 7 days of HIV infection with 5 days of 
nanoformulation treatment, which clearly shows that drug 
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is getting released in sustained manner over a period of 
5 days and is able to activate latent cells and suppress the 
viral replication.
Discussion
Adherence to dosing regimens is a critical issue for HIV 
treatment and its prevention. It has been hypothesized that 
the development of approaches eliminating or reducing the 
effect of individual adherence could increase the efficacy of 
treatment strategies and provide for the prevention of HIV 
transmission. Considering this scenario, there is a need to 
develop new and innovative sustained-release antiviral 
formulations for better treatment of HIV (peripheral or 
central nervous system) disease and the prevention of HIV 
transmission and acquisition. Magnetite (Fe
3
O
4
) is the most 
commonly used MNP in the field of biomedicine, mainly 
because of its biocompatibility. In this study, ultrasmall 
MNPs were developed by the coprecipitation method (the 
main advantage of this method is its circumstance-friendly 
and cost-effective method of preparation on the nanoscale) 
and tested for their drug-loading, in vitro release pharma-
cokinetics, cytotoxicity, and in vitro antiviral replication 
efficacy in central nervous system cells. The most important 
parameters affecting release behavior were identified and 
optimized. The superparamagnetism can be used for simul-
taneous monitoring and quantitation of MNP (specific or 
nonspecific) distribution to various tissues.
Distribution of charge on the surface of synthesized 
MNPs was determined by measuring the zeta potential. The 
zeta-potential values clearly demonstrated that the surface 
charge of the MNPs reverses on coating of alternately 
charged moieties (tenofovir/DS coating), proving that 
multilayer build-up is taking place. The desired system is 
expected to achieve complete release of the drug in 5–7 days 
to overcome the problem of frequent dosing and better patient 
adherence. To achieve 100% drug release over a period of 
1 week with zero-order release kinetics, different amounts 
of tenofovir were used for loading. It was observed that drug 
loading of MNPs does not increase with increasing the drug 
amount to the nanoparticles. In most cases, drugs are either 
directly immobilized or loaded on the nanocarrier surface 
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Figure 10 Evaluation of antiviral efficacy of nanoformulation in suppressing p24 antigen levels in HIV-infected human astrocytes.
Notes: Nanoformulations were added on the second day after HIV infection (HIV-1BaL) in equimolar concentration. Supernatants were evaluated on third, fifth, and seventh 
day postinfection for p24 levels and were checked for its efficacy, along with its percentage cell viability, using MTT assay. Simultaneous incorporation of tenofovir and 
vorinostat into the magnetic nanoparticles’ nanoformulation leads to latent virus activation and inhibits viral spread almost comparable to tenofovir nanoformulation. Viral 
p24 protein in the culture supernatant was measured by enzyme-linked immunosorbent assay. error bars indicate the standard deviation of triplicate data points and are 
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or tethered via adsorption or immobilization (coating) of 
organic/inorganic surfactants (eg, polyethylene glycol).29,30 
In either case, attached drugs are exposed to the external 
environment and possess the threat of rapid decomposi-
tion because of metabolic (enzymatic mainly) activity of 
the peripheral circulation (blood) before it could reach the 
target.14,18 Even though the nanoparticles have a high surface 
area, one of the major limitations in drug delivery is their low 
drug-loading capacity, which could be a problem in the devel-
opment of long-term or sustained-release formulations.
To avoid the abovementioned problems, scientists have 
used a hybridization strategy in which nanoparticle formula-
tion is encapsulated in liposomes,18,31 and this nanoformula-
tion has developed as a possible solution, but the limitation 
with this technique is that it increases the size of nanoformu-
lation up to +100 nm, which makes the formulation less able 
to cross the BBB.32–34 Considering these limitations, we have 
proposed, for the first time, the use of LbL methodology23,35 
(spontaneous adsorption of alternating layers of positively 
and negatively charged species). This technique is simple, 
fast, and versatile and helps in loading more drugs as a result 
of the electrostatic interaction between oppositely charged 
layers. The rate of release can also be adjusted through shell 
thickness, which can be controlled according to layer num-
bers. Another advantage of this thin film nanoengineered 
architecture deposition is the precision of layer thickness 
control that is within the range of 3–5 nm (each layer), 
which helps in maintaining the size of nanoparticles within 
the desirable range.
Therefore, to achieve sustained drug release, a LbL self-
assembly technique was applied to the MNPs, helping to 
reduce the initial burst and prolonging the period of release in 
the induction phase without significantly affecting the release 
rate. Our results demonstrate that the zeta potential of nano-
particle formulation reversed on the addition of oppositely 
charged polyelectrolyte and drug (DS/tenofovir)
2
 coatings, 
causing greater stability of nanoparticles, as indicated by the 
greater negative and positive charges. Electrostatic interac-
tions between the nanoparticles and the polyelectrolytes are 
the main driving force for multilayer build-up. These interac-
tions seem to be strong enough; otherwise, the adsorbed lay-
ers would be removed on the adsorption process of the next 
polyelectrolyte layer, as evident by zeta-potential analysis. 
Results showed that LbL significantly reduced the tenofovir 
initial burst threefold and increased the duration of drug 
release (30 times) in the induction phase (4 versus 120 hours). 
In the case of vorinostat-uncoated MNP release, there was a 
slow release of vorinostat because of its low water solubility 
(7 hours) compared with that of uncoated MNPs loaded with 
tenofovir (4 hours).
Cytotoxicity testing of the nanoformulation is highly recom-
mended and is considered one of the most fundamental tests for 
biocompatibility. The aim of cytotoxicity studies is to evaluate 
the in vitro biocompatibility of a drug-loaded polyelectrolyte-
coated nanoformulation in different brain cells. Different cellular 
aspects were analyzed to determine the cell viability in HAs, 
such as cell uptake, adhesion, proliferation, and morphology. 
The results provided good evidence of adhesion, growth, and 
morphology, with more than 95% of cell viability in cases of 
all different concentrations of nanoformulation. Flow cytometer 
analysis of cellular uptake shows a concentration-dependent 
increase in cell uptake, which is evident from the increase in 
mean fluorescence intensity and increased percentage of cells 
positive for FITC-tagged nanoformulation. Furthermore, the 
effect of the magnetic field on the transmigration ability and 
BBB integrity of the formulation was evaluated, and results show 
there was no damage to the BBB and that more than 40% of the 
nanoformulation crosses the BBB only after the application of 
6 hour magnetic field. To achieve higher transmigration of the 
formulation, we have optimized the important para meters of 
magnetic field and time of application. The results demonstrate 
the ability of our nanoformulation system to be efficiently 
taken up into the cells and provide a platform with which we 
can effectively deliver our cargo of interest (ie, an HIV-latency 
activator [vorinostat] and nucleotide reverse transcriptase inhibi-
tor [tenofovir]). The integrity of the release drug after the mag-
netic field was evaluated using mass spectroscopy and checked 
for its antiviral replication efficacy. Our results demonstrate 
that free standard drug displays inhibition equal to that of the 
released nanoformulation. To test the ability of nanoformulation 
([MNP+tenofovir]
2
+vorinostat) to activate latent virus, we used 
the HA cell culture system. In addition, the long-term sustained-
release behavior was studied directly in the HIV-infected HA 
cell culture system. Results were very positive; nanoformulation 
can effectively control virus spread up to 5 days in a continuous 
manner, while at the same time being able to stimulate latent 
HIV expression in HA cells, as evident in the results.
Conclusion
In conclusion, the current work is an in vitro proof of study 
demonstrating that latency-breaking agents can be pack-
aged into nanoparticles in conjunction with an antiretroviral 
drug. We successfully established the application of the 
LbL assembly technique by achieving long-term release 
(5 days) across the BBB in a sustained manner. Further, we 
combined the synergistic effect of vorinostat and tenofovir 
Powered by TCPDF (www.tcpdf.org)
                               1 / 1
International Journal of Nanomedicine 2015:10 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
1089
sustained-release nanoarT formulation for the treatment of neuroaIDs
in a single nanoformulation and demonstrated the ability of 
nanotechnological approaches to provide improved methods 
for activating latent viruses and killing them simultaneously. 
Novel drug delivery systems such as the one described 
here may enhance the future of HIV therapy by using 
combination therapy of ARV drugs (ie, [nucleotide reverse 
transcriptase inhibitor+nucleotide reverse transcriptase 
inhibitor+protease inhibitor] or [nucleotide reverse tran-
scriptase inhibitor+protease inhibitor+integrase inhibitor]) 
to achieve better efficacy and complete the eradication of 
the virus from the central nervous system. In the future, 
in vivo studies will be performed using the HIV-infected 
severe combined immunodeficiency mouse model to assess 
the free drug amount (microdialysis) present in the brain 
parenchyma to evaluate the therapeutic efficacy of the 
nanoformulation.
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Figure S1 Dls measurement of hydrodynamic diameter with respect to drug loading and layer-by-layer assembly deposition.
Abbreviations: Dls, dynamic light scattering; MNP, magnetic nanoparticle.
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Figure S2 Mass spectrometry analysis. 
Note: Mass spectrometry instrumental parameters used for the lc/MsD analyses (general screening Method).
Abbreviations: lc/MsD, liquid chromatography–mass spectrometry data; temp, temperature; Vcap, capillary voltage; min, minute.
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Figure S3 Mass spectroscopy analysis. 
Notes: The number of counts versus the mass-to-charge ratio (standard peak of 288) for (A) the standard free tenofovir (1:10 water dilution); (B) released tenofovir from 1 
bilayer formulation (MNP+tenefovir+dextran sulphate); and (C) released tenofovir from 2 bilayers formulation ([tenofovir+dextran sulphate]2+vorinostat). [M+h]+ indicates 
protonated molecular ions of the formula in positive ionisation mode.
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Figure S5 p24 study to show effect of standard (free drug) vorinostat on hIV replication in human astrocytes. 
Note: Different ranges of vorinostat (0.5–5 µm) were used; results show maximum p24 value at 1µM concentration, which is used for the nanoformulation development.
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Figure S4 cell viability of neuronal cells (sK-N-Mc cells) with MNP nanoformulation.
Note: results show the percentage of cells viable after treatment with different concentrations of (50–200 µg/ml) for 24 hours.
Abbreviation: MNP, magnetic nanoparticles.
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